Who Are the Leaders in the Emerging Biosimilar Drugs Market? Visiongain’s New Analysis Gives Company Assessments, Discussions and Predictions Where are companies in the Biosimilar market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead Our 233-page report provides 126 tables, charts, and graphs, giving a clear view on companies in the biosimilar market. Who are the most important and promising biosimilar drug companies? And what are their sales potentials? Discover this information in our updated report, which analyses 25 leading developers, producers and marketers of biosimilars. The report also covers other firms, including big pharma companies entering that industry.
Molecules giving rise to biosimilars – explore where progress occurs Our report discusses biosimilar competition for these five therapeutic agents – products and research and development: • Adalimumab • Infliximab • Etanercept • Darbepoetin alpha • Rituximab.
In particular, our report analyses 25 leading biosimilar specialists worldwide. First of all, Chapter 4 gives profiles of leading biosimilar companies based in the US, Western Europe and Israel: • Hospira (Pfizer) • Mylan • Sandoz (Novartis) • STADA Arzneimittel • Teva Pharmaceutical Industries
Chapter 5 profiles leading companies in China: • 3SBio • Beijing ShuangLu Pharmaceutical Co. • Qilu Pharmaceutical • Shanghai Fosun Pharmaceutical Group • Tonghua Dongbao Pharmaceutical Co.
Chapter 6 profiles leading companies in India: • Biocon • Dr. Reddy’s Laboratories • Intas Biopharmaceuticals • Ranbaxy (Sun Pharma) • Reliance Life Sciences • Wockhardt • Zydus Cadila
Chapter 7 profiles leading companies in Latin America: • Amega Biotech • Biosidus • Probiomed
Chapter 8 profiles leading companies in the rest of the world: • Biocad • Bioton • Celltrion • Dong-A • LG Life Sciences
Our report also reviews 25 other companies rising in importance. See what is possible from 2017, discovering what leading companies do and their commercial outlooks.
With our report, you will see who and what shapes the biosimilars industry, including policies, regulatory concerns and other forces influencing those companies and their market, affecting its revenues and profits. Discover what the future holds for leading organisations.
How the 25 Top Biosimilar Drug Manufacturers report helps you In summary, our 233-page report provides you with the following knowledge: • Profiles of 25 leading biosimilar companies and other relevant firms – assess products, results, strategies, technologies and outlooks, also gaining company level revenue forecasting for five leading producers’ biosimilar drug sales • R&D for biosimilars – see activities by company, finding what goes on in that industry, investigating its technological and commercial potentials • Competition and opportunities – explore what affects the biosimilars market, finding what shapes its future, especially prospects for developing business
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Visiongain’s study is for everybody needing commercial analyses for the leading companies in the Biosimilar market. You will find data, trends and predictions.
Get our report today Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers, 2017-2027, and Other Rising Companies – a Market Report Assessing Developers and Producers of Competitor Biologics. Avoid missing out – get our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Overview of the Top Biosimilar Drug Manufacturers 1.2 Why You Should Read This Report 1.3 How This Report Delivers 1.4 Main Questions Answered by This Analytical Study 1.5 Who is This Report For? 1.6 Methodology 1.7 Frequently Asked Questions (FAQ) 1.8 Associated Visiongain Reports 1.9 About Visiongain
2. Biosimilar Drugs: World Market Forecast, 2017-2027 2.1 Introduction to Biologics and Biosimilars 2.1.1 Biologic Drugs Definition and Overview 2.1.2 Biosimilars Drugs Definition and Overview 2.1.3 How do Biosimilars Differ from Generics? 2.2 The World Biosimilar Market, 2017-2027 2.3 Overall World Biosimilars Revenue Forecast, 2017-2027 2.4 Biosimilars – Realising their Potential, Market Drivers 2.4.1 Biosimilar Approval Pathways and Regulations 2.4.2 India Releases New Biosimilar Development Guidelines 2.4.3 Russia: Lack of Regulatory Framework Works Well in the Short Term 2.4.4 ‘Pharma 2020’ Initiative 2.4.5 South Korean Market has benefitted from Early Biosimilar Guidelines 2.4.6 Chinese FDA Publishes Finalised Biosimilar Guidelines in 2016 2.4.7 Brazil: ANVISA’s Biosimilar Regulations Are Similar the EMA’s 2.4.8 The Outlook for Biosimilar mAbs in the EU 2.4.9 The Outlook for Biosimilar mAbs in Japan 2.4.10 Emerging Markets for Biosimilars 2.4.11 Start-up Pressure on Market Leaders 2.4.12 The Patent Cliff for Biologics 2.5 Biosimilars: Market Restraints 2.5.1 Market Fragmentation for Biosimilar Products 2.5.2 Innovative Biologics – Rendering Biosimilars Useless? 2.5.3 Biobetters – A Growing Threat 2.5.4 BREXIT and Trump Election – A Rising Political Threat
4. Leading Biosimilar Manufacturers in the United States, Western Europe and Israel, 2017 4.1 Sandoz – Company Overview & Analysis 4.1.1 Sandoz Biosimilar Products 4.1.2 Sandoz Biosimilars Market Forecast, 2017-2027 4.1.3 Sandoz Biosimilars R&D Pipeline & Future Outlook 4.2 Teva Pharmaceuticals – Company Overview & Analysis 4.2.1 Teva Biosimilar Products 4.2.2 Teva Biosimilar Market Forecast, 2017-2027 4.2.3 Teva Biosimilar Pipeline & Future Outlook 4.3 Hospira (Pfizer) – Company Overview & Analysis 4.3.1 Hospira Biosimilar Products 4.3.2 Hospira Biosimilars Pipeline & Future Strategies 4.4 STADA Arzneimittel – Company Overview & Analysis 4.4.1 STADA Biosimilar Products 4.4.2 STADA Biosimilars Pipeline & Future Outlook 4.5 Mylan – Company Biosimilar & Analysis 4.5.1 Mylan Biosimilar Products 4.5.2 Mylan Biosimilar Market Forecast, 2017-2027 4.5.3 Mylan Biosimilars Pipeline & Future Outlook 4.6 Other Biosimilars Companies in the US 4.6.1 Impax Laboratories Inc. – Company Overview & Analysis 4.6.2 Bristol-Myers Squibb – Company Overview & Analysis 4.6.3 Merck & Co. – Company Overview & Analysis 4.6.4 Eli Lilly - Company Overview & Analysis 4.7 Other Biosimilar Companies in Europe 4.7.1 BioXpress Therapeutics – Company Overview & Analysis 4.7.2 Medice Arzneimittel Pütter GmbH & Co. KG – Company Overview & Analysis 4.7.3 Finox Biotech – Company Overview & Analysis
5. Leading Biosimilar Manufacturers in China, 2016 5.1 S3Bio – Company Overview & Analysis 5.1.1 3SBio Biosimilar Products 5.1.2 3SBio Biosimilars Market Forecast, 2017-2027 5.1.3 3SBio Biosimilars Pipeline & Future Outlook 5.2 Qilu Pharmaceutical – Company Overview & Analysis 5.2.1 Qilu Pharmaceutical Biosimilar Products 5.2.2 Qilu Pharmaceutical Biosimilars Pipeline & Future Outlook 5.3 Shanghai Fosun Pharmaceuticals – Company Overview & Analysis 5.3.1 Shanghai Fosun Pharmaceuticals Biosimilar Products 5.3.2 Shanghai Fosun Pharmaceuticals Biosimilars Pipeline & Future Strategy 5.4 Tonghua Dongbao – Company Overview & Analysis 5.4.1 Tonghua Dongbao Biosimilar Products 5.4.2 Tonghua Dongbao Biosimilars Pipeline & Future Strategies 5.5 Beijing ShuangLu Pharmaceuticals – Company Overview & Analysis 5.5.1 Beijing ShuangLu Pharmaceuticals Biosimilar Products 5.5.2 Beijing ShuangLu Pharmaceutical Biosimilars Pipeline & Future Outlook 5.6 Other Biosimilars Companies in China 5.6.1 Shanghai CP Guojian – Company Overview & Analysis 5.6.2 Zhejiang Hisun – Company Overview & Analysis 5.6.3 Innovent Biologics – Company Overview & Analysis 5.6.4 Shanghai Celgen Biopharmaceutical – Company Overview & Analysis
6. Leading Biosimilar Manufacturers in India, 2016 6.1 Biocon – Company Overview & Analysis 6.1.1 Biocon Biosimilar Products 6.1.2 Biocon Biosimilars Market Forecast, 2017-2027 6.1.3 Biocon Biosimilars Pipeline & Future Outlook 6.2 Dr. Reddy’s Laboratories – Company Overview & Analysis 6.2.1 Dr. Reddy’s Laboratories Biosimilar Products 6.2.2 Dr. Reddy’s Laboratories Biosimilars Pipeline & Future Outlook 6.3 Wockhardt – Company Overview & Analysis 6.3.1 Wockhardt Biosimilar Products 6.3.2 Wockhardt Biosimilars Pipeline & Future Outlook 6.4 Zydus Cadila – Company Overview & Analysis 6.4.1 Zydus Cadila Biosimilar Products 6.4.2 Zydus Cadila Biosimilars Pipeline & Future Outlook 6.5 Ranbaxy (Sun Pharma) – Company Overview & Analysis 6.5.1 Ranbaxy Biosimilar Products 6.5.2 Ranbaxy Biosimilars Pipeline & Future Outlook 6.6 Reliance Life Sciences – Company Overview & Analysis 6.6.1 Reliance Life Sciences Biosimilar Products 6.6.2 Reliance Life Sciences Biosimilars Pipeline & Future Outlook 6.7 Intas Biopharmaceuticals – Company Overview & Analysis 6.7.1 Intas Biopharmaceuticals Biosimilar Products 6.7.2 Intas Biopharmaceuticals Biosimilars Pipeline & Future Outlook 6.8 Other Indian Biosimilars Companies 6.8.1 Emcure Pharmaceuticals – Company Overview & Analysis 6.8.2 Shreya Life Sciences – Company Overview & Analysis 6.8.3 Cipla – Company Overview & Analysis 6.8.4 Shantha Biotechnics – Company Overview & Analysis
7. Leading Biosimilar Manufacturers in Latin America, 2016 7.1 Probiomed – Company Overview & Analysis 7.1.1 Probiomed Biosimilar Products 7.1.2 Probiomed Biosimilars Pipeline & Future Strategies 7.2 Biosidus – Company Overview & Analysis 7.2.1 Biosidus Biosimilar Products 7.2.2 Biosidus Biosimilars Pipeline & Future Strategies 7.3 Amega Biotech – Company Overview and Analysis 7.3.1 Amega – Biosimilar Products 7.3.2 Amega Biotech Biosimilars Pipeline & Future Strategies 7.4 Other Biosimilars Companies in South America 7.4.1 Bionovis – Company Overview & Analysis 7.4.2 Orygen Biotecnologia – Company Overview & Analysis 7.4.3 Recepta – Company Overview & Analysis
8. Leading Biosimilar Manufacturers in the Rest of the World, 2016 8.1 Celltrion – Company Overview & Analysis 8.1.1 Celltrion Biosimilar Products 8.1.2 Celltrion Biosimilars Pipeline & Future Strategies 8.2 LG Life Sciences – Company Overview & Analysis 8.2.1 LG Life Sciences Biosimilar Products 8.2.2 LG Life Science Biosimilars Pipeline & Future Strategies 8.3 Dong-A – Company Overview & Analysis 8.3.1 Dong-A Biosimilar Products 8.3.2 Dong-A Biosimilars Pipeline & Future Strategies 8.4 Bioton – Company Overview & Analysis 8.4.1 Bioton’s Biosimilar Products 8.4.2 Bioton’s Biosimilars Pipeline & Future Strategies 8.5 Biocad – Company Overview & Analysis 8.5.1 Biocad’s Biosimilar Products 8.5.2 Biocad’s Biosimilars Pipeline & Future Strategies 8.6 Other Biosimilars Companies in the RoW 8.6.1 Gedeon-Richter – Company Overview & Analysis 8.6.2 Egis Pharmaceuticals - Company Overview & Analysis 8.6.3 JCR Pharmaceuticals – Company Overview & Analysis 8.6.4 Nippon Kayaku – Company Overview & Analysis 8.6.5 Fujifilm Kyowa Kirin Biologics – Company Overview & Analysis 8.6.6 Daiichi Sankyo – Company Overview & Analysis
9. Qualitative Analysis of Biosimilars Market: 2017-2027 9.1 SWOT Analysis of the Global Biosimilars Industry and Market: 2017-2027 9.1.1 Strengths 9.1.2 Weaknesses 9.1.3 Opportunities 9.1.4 Threats 9.2 STEP Analysis of the Global Biosimilars Industry and Market: 2017 -2027 9.2.1 Social Factors 9.2.2 Technological Factors 9.2.3 Economic Factors 9.2.4 Political Factors
10. Conclusions 10.1 Market Leaders Among Biosimilar Manufacturers 10.2 Will Sandoz Retain its Position as Market Leader? 10.3 Which Companies Are Best Placed to Lead in Future? 10.4 Big Pharma Companies Will Try Gain Market Entry 10.5 Contribution of Chinese and Indian Companies will Grow 10.6 Strong R&D Pipeline – Driver for Growth 10.7 Concluding Remarks
Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form
Abbott Laboratories Abbvie Actavis Alvogen Ambrx Amega Biotech Amerigen Pharmaceuticals Amgen ANVISA Apotex Inc ASKA Pharmaceuticals AstraZeneca Baxter Beijing ShuangLu Pharmaceuticals Bio Technology General Corporation Bioceuticals Biocon Biogen Idec Biogenerics Arzneimittel BioMab Bionovis BioPartners Biosidus Bioton BioXpress Therapeutics Boehringer Ingelheim Bristol-Myers Squibb Catalent Pharma Solutions Cell Pharm Celltrion Ciba-Geigy Cipla Biotech CITIC Group Coherus Biosciences Daiichi Sankyo Dainippon Sumitomo Pharma DM Bio plant Dong-A Dr. Reddy’s Laboratories Egis Pharmaceutical Eisai Eli Lilly Emcure Pharmaceuticals Epirus Pharmaceutical Ferring Pharmaceuticals Finox Biotech Fujifilm Kyowa Kirin Biologics Gan & Lee Pharmaceutical Gedeon Richter Genentech GeneriCo, LLC GeneScience Gland Pharma GSK Hangzhou Jiuyuan Gene Engineering Co Hexal Hospira Hualida Biotech Impax Laboratories Inc Innovent Biologics Intas Biopharmaceuticals Janssen Biotech JCR Pharmaceuticals Johnson & Johnson Kwizda Pharma LG LG Chem Investment (LGCI) LG Life Sciences MabPharm Marvel Life Sciences Medice Arzneimittel Meiji Seika Pharmaceutical Merck KGa Merck Serono Mitsubishi Tanabe Momenta Pharmaceuticals Mylan Nippon Kayaku NovaQuest Novartis Novo Nordisk Orygen Biotecnologia Owen Mumford Pfizer Pilva Probiomed Qilu Pharmaceutical Ranbaxy Ratiopharm Recepta Reliance Life Sciences Richter-Helm BioTec GmbH& Co. KG Roche Royal DSM Samsung Bioepis Sandoz Sanofi Sanwa Kenkyusho Co. Ltd Savient Pharmaceuticals Shandong Kexing Pharma Shanghai Celgen Biopharmaceuticals Shanghai CP Guojian Shanghai Fosun Pharmaceutical Shanghai Henlius Biotech Shanghai Lansheng Guojian Pharmaceutical Co. Ltd Shanghai Stock Exchange Shantha Biotechnics Shenyang Sunshine (3SBio) Shreya Life Sciences Sicor Sidus Pharmaceutical Group Stada Arzneimittel Sumitomo Pharmaceuticals Sun Pharma Takeda Teva Tonghua Dongbao WHO Wockhardt Xiamen Amoytop Biotech Ypsomed Zhejiang Hisun Zydus Cadila
List of Organisations Biopharmaceuticals and Herbal Medicines Bureau South Korea Central Drugs Standard Control Organisation Centre for Drug Evaluation China National Pharmaceutical Group (Sinopharm) Chinese Food & Drug Administration (CFDA) Committee for Medicinal Products for Human Use (CHMP) European Medicine Agency (EMA) European Union (EU) Financier of Studies and Projects (FINEP) US Food and Drug Administration (FDA) International Labour Organization (ILO) Korean Food and Drug Administration Ludwig Institute for Cancer Research Medicine and Healthcare Products Regulatory Agency (MHRA) Ministry of Health, Labor and Welfare (MHLW) National Autonomous University of Mexico (UNAM) National Council for Science and Technology (CONACyT) National Health Service (UK) Therapeutic Goods Administration (TGA) World Health Organisation (WHO)
Download sample pages
Complete the form below to download your free sample pages for Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.